Jazz Pharmaceuticals PLC (NAS:JAZZ)
$ 109.74 -2.27 (-2.03%) Market Cap: 6.92 Bil Enterprise Value: 11.03 Bil PE Ratio: 22.63 PB Ratio: 1.87 GF Score: 78/100

Jazz Pharmaceuticals PLC at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 02:55PM GMT
Release Date Price: $175.09 (-0.97%)
Daniel James Busby
RBC Capital Markets, Research Division - Assistant VP

All right. Thanks, everyone, for joining us. I'm Dan Busby, the pharmaceuticals analyst at RBC Capital Markets. And our next company presenting today is Jazz Pharmaceuticals. You are just 2 weeks removed from the close of the company's GW Pharmaceuticals acquisition, so it's a very opportune time to have a conversation.

I'm joined this morning by Jazz Chairman and CEO, Bruce Cozadd, former GW Pharma CEO, Justin Gover; Dan Swisher, President; and Rob Iannone, EVP, R&D and Chief Medical Officer. Bruce, before we jump into Q&A, I'd like to give you the opportunity to provide some brief opening comments.

Jazz is a very different company today than it was just a few years ago. So where do we stand in the company's transformation? And what's still to come?

Bruce C. Cozadd
Jazz Pharmaceuticals plc - Co-Founder, Chairman & CEO

Yes, Dan, thanks for the opportunity to be here. And you're right. We are a different company from a few years ago. I'd say we're a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot